Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized 4-period crossover pharmacokinetic study of four FT218 6 g formulations in healthy volunteers
NL-OMON48344Active, not recruiting
- Sponsor
- Avadel Pharmaceuticals
- Start
- Dec 2019
- Modality
- Cell Therapies, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of AV001 in narcolepsy (4 arms), sponsored by Avadel Pharmaceuticals. Primary endpoint: Bioequivalence of sodium oxybate pharmacokinetics. Started Dec 2019; status: active, not recruiting.
02
Drugs
AV001
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NL-OMON48344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48344.